<DOC>
	<DOC>NCT02384811</DOC>
	<brief_summary>The primary object of this trial is to evaluate the 2-year local control rate adding extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma.</brief_summary>
	<brief_title>Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Joined the study voluntarily and signed informed consent form; Age 1875；ECOG 02 Esophageal squamous cell carcinoma , radical surgery ≤3 months,R0 resection. The operative incision healed well. T34N0M0, T14N13M0 (according to AJCC2009) No radiotherapy, chemotherapy or other treatments pre(post)surgery PS ECOG 02 Life expectancy of more than 3 months Hemoglobin(Hb)≥9 g/dL • WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L • platelet count (Pt) ≥100x 109/L • Hepatic function: ALAT and ASAT &lt; 2.5 x ULN, TBIL&lt;1.5 x ULN • Renal function: creatinine &lt; 1.5 x ULN No immunodeficiency Use of an effective contraceptive for adults to prevent pregnancy. Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years Participation in other interventional clinical trials within 30 days Pregnant or breastfeeding women or people during the birthperiod who refused to take contraceptives Drug addiction, Alcoholism or AIDS Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior Unsuitable to be enrolled in the trial in the opinion of the investigators</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Esophageal squamous cell carcinoma</keyword>
	<keyword>postoperative radiotherapy</keyword>
</DOC>